newsletter and steinberg, page-2

The newsletter is a great idea.

I'm really wondering what's going on with the dental trials. A Japanese company aiming to use bos's compound for a mouthwash might suggest some promising results of the dental trials are being shared with potential manufacturers.

The lenses are down-played considerably.

Anti-bacterial packaging company Novamont is a hopeful sign. The more work with attaching bos's compound to materials the more likely the catheters and lenses will get up and running. Ciba's trials in attaching compound to materials should conclude in about Oct 07. Very little feed-back on how that's been going.

I've got many, many questions on biosignal. I feel there's still a great deal of research to be done, but the upside is considerable.

I'm impressed with the crew at bos at the moment. With so few staff they must be working very hard with reporting requirements on top of running the company.